---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000091"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:39:51.443001+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Gossamer Bio provides interim TORREY OLE data and PROSERA Phase 3 trial design

## Summary
- Announced interim data from open-label extension of seralutinib in PAH patients.
- Detailed design of planned Phase 3 PROSERA trial for seralutinib.
- No specific efficacy or safety numbers disclosed in the filing or exhibit.
- Corporate presentation furnished as Exhibit 99.1 contains the update.

## SEC filing metadata
- accession: 0001728117-23-000091
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000091/0001728117-23-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000091/goss-20230720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000091
- JSON: https://secwatch.observer/filing/0001728117-23-000091.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.